主动监测期间进展后接受根治性放疗与前期根治性放疗的前列腺癌结局比较
本研究比较了主动监测(AS)后疾病进展再接受根治性放疗与风险匹配的前期根治性放疗患者结局。AS后放疗组5年生化无复发生存率97%、无转移生存率99%、总生存率98.5%,无前列腺癌死亡;多因素分析中放疗时机(延迟与前期)与生化复发或转移发生无关。
要点
- AS后进展再放疗的5年bRFR、mFR、OS分别为97%、99%、98.5%。
- 放疗时机(延迟 vs 前期)与生化复发或转移无关。
核心结论
- 主动监测一段时间后接受根治性放疗(剂量递增IGRT或LDR-BT)在5年时获得优异的肿瘤学结局。
- 与风险特征相似的前期治疗患者相比,AS后延迟根治性治疗似乎不会导致更差的肿瘤学结局。
研究设计与样本
- 前瞻性AS注册队列中1992至2014年入组、随后接受根治性放疗(IGRT或LDR-BT)的200例患者。
- 与按年龄、临床预后指标(风险组、PSA、cT分期、Gleason评分、阳性活检核心百分比)和放疗方式匹配的359例前期治疗队列进行比较。
主要发现
- AS注册的1070例患者中200例接受根治性放疗(143例IGRT和57例LDR-BT),AS中位时间32.9个月(IQR 20.6-59.8)。
- 治疗主要原因分别为分级升级(57.5%)和体积升级(26%)。
- 放疗后中位随访4.9年(IQR 3.1-7.5),5年bRFR、mFR、OS分别为97%、99%、98.5%,无前列腺癌死亡。
- 多因素分析中根治性放疗时机(延迟 vs 前期)与生化复发或转移发生无关。
关键数值与推荐
- AS后接受根治性放疗的5年bRFR为97%、mFR为99%、OS为98.5%。
临床怎么用
- 对初始 presumed 惰性前列腺癌患者,AS期间进展后接受剂量递增IGRT或LDR-BT可获得与前期放疗相当的肿瘤学结局。
- AS后延迟根治性放疗可作为合适患者的选择,不必然导致更差的疾病特异性结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe and compare outcomes in men with initially presumed indolent prostate cancer receiving definitive radiation therapy after active surveillance (AS) versus those in a risk-matched cohort undergoing up-front radiation therapy. METHODS AND MATERIALS: Men prospectively enrolled in an AS program between 1992 and 2014 and subsequently undergoing curative radiation therapy (ie, image guided radiation therapy [IGRT] or low-dose-rate brachytherapy [LDR-BT]) were identified. Biochemical relapse-free rate (bRFR), metastasis-free rate (mFR), and overall survival (OS) were compared against a cohort of men treated up front, matched by age, clinical prognostic indices (risk group, prostate-specific antigen, cT category, Gleason score, percentage of involved biopsy cores), and radiation therapy modality. RESULTS: Of 1070 patients in the AS registry, 200 underwent definitive radiation therapy (143 IGRT and 57 LDR-BT) after a median of 32.9 (interquartile range [IQR] 20.6-59.8) months on surveillance. Main reasons for treatment were grade and volume upgrading (57.5% and 26%, respectively). Median follow-up after radiation therapy was 4.9 (IQR 3.1-7.5) years. At 5 years the bRFR, mFR, and OS were, respectively, 97%, 99%, and 98.5%. No patient died of prostate cancer. Adequate risk-matching was confirmed in an independent cohort comprising 359 patients receiving up-front IGRT (71%) or LDR-BT (29%) and followed for a median of 9 (IQR 3.1-7.5) years. There was no difference in the disease-specific outcomes (bRFR, mFR) between the 2 cohorts (Gray's P value of .257 and .934, respectively). In multivariate analyses, timing of radical radiation therapy (deferred vs up-front) was not correlated to biochemical relapse or metastases occurrence. CONCLUSIONS: Curative-intent radiation therapy (ie, dose-escalated IGRT or LDR-BT) after a period of AS renders excellent oncologic outcomes at 5 years. Deferring radical therapy after a period of AS does not seem to result in inferior oncologic outcomes compared with patients with similar risk characteristics undergoing up-front treatment.
引用
- Berlin A, Ahmad AE, Chua MLK, et al. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29249526. doi:10.1016/j.ijrobp.2017.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。